Sidley represented Aquestive Therapeutics, Inc. (Nasdaq: AQST) in an exclusive license agreement and a supply agreement with Eton Pharmaceuticals, Inc. (Nasdaq: ETON) for Libervant® (diazepam) buccal film, an orphan-designated treatment for seizure clusters in patients with epilepsy. Under the license agreement, Eton receives exclusive commercialization rights to Libervant in the United States and its territories. Libervant targets a U.S. market estimated at more than US$450 million annually, with commercial launch anticipated in April 2027, subject to final approval by the U.S. Food and Drug Administration.
The Sidley team was led by Jennifer Raab (Technology and Life Sciences Transactions), and included Yuhan Wu and Jonathan Trang (Technology and Life Sciences Transactions); and Steven Przesmicki (Emerging Companies and Venture Capital).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
